Your browser doesn't support javascript.
Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections.
Matsuba, Ikuro; Takuma, Tetsuo; Hatori, Nobuo; Takai, Masahiko; Watanabe, Yoshiyuki; Takada, Nobukazu; Kishi, Satoru; Matsuzawa, Yoko; Nishikawa, Tetsuo; Kunishima, Tomoyuki; Degawa, Hisakazu; Nishikawa, Masanori; Ono, Yoshiaki; Kanamori, Akira.
  • Matsuba I; Kanagawa Physicians Association, Japan.
  • Takuma T; Kanagawa Physicians Association, Japan.
  • Hatori N; Kanagawa Physicians Association, Japan.
  • Takai M; Kanagawa Physicians Association, Japan.
  • Watanabe Y; Kanagawa Physicians Association, Japan.
  • Takada N; Kanagawa Physicians Association, Japan.
  • Kishi S; Kanagawa Physicians Association, Japan.
  • Matsuzawa Y; Kanagawa Physicians Association, Japan.
  • Nishikawa T; Kanagawa Physicians Association, Japan.
  • Kunishima T; Kanagawa Physicians Association, Japan.
  • Degawa H; Kanagawa Physicians Association, Japan.
  • Nishikawa M; Kanagawa Physicians Association, Japan.
  • Ono Y; Kanagawa Physicians Association, Japan.
  • Kanamori A; Kanagawa Physicians Association, Japan.
Intern Med ; 61(2): 159-165, 2022 Jan 15.
Article in English | MEDLINE | ID: covidwho-1622449
ABSTRACT
Objective To examine the continuation of antibody prevalence and background factors in antibody-positive subjects after asymptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods A study was carried out to investigate the SARS-CoV-2 antibody (IgG) prevalence. SARS-CoV-2 antibodies (IgG) were measured and analyzed with immunochromatographic tests. Patients Among 1,603 subjects, comprising patients, physicians, and nurses at 65 medical institutes in Kanagawa, Japan, 39 antibody-positive subjects received follow-up for 6 months. Results Of the 33 subjects who consented to the follow-up (23 patients and 10 medical professionals), continued positivity of IgG antibodies was confirmed in 11 of 32 cases (34.4%) after 2 months, 8 of 33 (24.2%) after 4 months, and 8 of 33 (24.2%) after 6 months. A significant difference was found in the sleeping time, drinking habits, hypertension, and use of angiotensin-receptor blockers on comparing subject background characteristics among three groups patients with antibody production that continued for six months after the first detection of positivity, patients in whom antibody production stopped at four months, and patients in whom antibody production stopped at two months. Conclusion The continuation rate of IgG antibody prevalence was 24.2% at 6 months after the first detection of antibody positivity in cases with asymptomatic coronavirus disease 2019 (COVID-19) infections. This percentage is low compared with the antibody continuation rate in patients who have recovered from symptomatic COVID-19 infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Intern Med Journal subject: Internal Medicine Year: 2022 Document Type: Article Affiliation country: INTERNALMEDICINE.8019-21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Intern Med Journal subject: Internal Medicine Year: 2022 Document Type: Article Affiliation country: INTERNALMEDICINE.8019-21